In older patients with Parkinson's disease (PD), the use of dopamine agonists (DA) has been limited due to uncertainties related to their tolerability in spite of potential gains with the advent of longer acting or transdermal therapies. Comparative real-life data addressing the tolerability of DA therapy across age ranges are currently sparse. This study addressed the tolerability (Shulman criteria, continued intake of DA therapy for at least 6 months) in PD patients across several European centres treated with long-acting and transdermal DA (Rotigotine skin patch, Ropinirole extended release, or Pramipexole prolonged release) as part of routine clinical care in younger and older PD patients. A medical record-based retrospective data capture and clinical interview-based follow-up survey of patients initiating or initiated on DA treatment (short and long acting) in a real-life setting. 425 cases were included [mean age 68.3 years (range 37-90), mean duration of disease 7.5 years (range 0-37), 31.5% older age (≥ 75 years of age)]. Tolerability was above 90% irrespective of age, with no significant differences between younger and older patients. Based on our findings, we suggest that long-acting/transdermal DA are tolerated in non-demented older patients, as well as in younger patients, however, with lower daily dose in older patients.

中文翻译：

---

非麦角口服和经皮多巴胺激动剂对年轻和年长帕金森病患者的耐受性：一项欧洲多中心调查。

在老年帕金森病 (PD) 患者中，多巴胺激动剂 (DA) 的使用受到限制，因为它们的耐受性存在不确定性，尽管随着长效或透皮疗法的出现可能会获得收益。解决跨年龄段 DA 治疗耐受性的比较现实数据目前很少。这项研究解决了几个欧洲中心接受长效和透皮 DA（罗替高汀皮肤贴剂、罗匹尼罗缓释或普拉克索缓释）治疗的 PD 患者的耐受性（舒尔曼标准，持续服用 DA 治疗至少 6 个月）作为年轻和年长 PD 患者常规临床护理的一部分。在现实生活环境中对开始或开始接受 DA 治疗（短效和长效）的患者进行基于病历的回顾性数据捕获和基于临床访谈的随访调查。包括 425 例 [平均年龄 68.3 岁（范围 37-90），平均病程 7.5 年（范围 0-37），年龄大 31.5%（≥ 75 岁）]。无论年龄大小，耐受性均高于 90%，年轻和年长患者之间没有显着差异。根据我们的研究结果，我们建议非痴呆老年患者和年轻患者可以耐受长效/透皮 DA，但老年患者的每日剂量较低。无论年龄大小，耐受性均高于 90%，年轻和年长患者之间没有显着差异。根据我们的研究结果，我们建议非痴呆老年患者和年轻患者可以耐受长效/透皮 DA，但老年患者的每日剂量较低。无论年龄大小，耐受性均高于 90%，年轻和年长患者之间没有显着差异。根据我们的研究结果，我们建议非痴呆老年患者和年轻患者可以耐受长效/透皮 DA，但老年患者的每日剂量较低。